Trials / Completed
CompletedNCT00233675
Evaluate the Safety of GABITRIL in Adults With Generalized Anxiety Disorder
A 12-Month, Open-Label, Flexible-Dosage Study to Evaluate the Safety of GABITRIL at Dosages up to 16mg/Day in Adults With Generalized Anxiety Disorder
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- —
- Sponsor
- Cephalon · Industry
- Sex
- All
- Age
- 18 Years – 64 Years
- Healthy volunteers
- Not accepted
Summary
To assess the long-term safety and tolerability of tiagabine treatment in patients with generalized anxiety disorder (GAD).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | GABITRIL (tiagabine hydrochloride; CEP-6671) |
Timeline
- Start date
- 2003-08-01
- Primary completion
- 2005-02-01
- First posted
- 2005-10-06
- Last updated
- 2023-04-12
Locations
28 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00233675. Inclusion in this directory is not an endorsement.